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Abstract. Psoriasin, otherwise known as S100A7, is a member of 
the S100 protein family. With the key function of binding calcium, 
it is able to regulate a range of cellular functions. Altered Psoriasin 
expression is associated with poor clinical outcomes in several 
solid cancers. The present study aimed to examine the implica‑
tion of Psoriasin in bladder cancer (BC). Expression of Psoriasin 
was examined in BC cell lines using PCR. Immunohistochemical 
(IHC) staining of Psoriasin was performed on a bladder disease 
spectrum tissue array. Plasmids were constructed to effectively 
knockdown and overexpress Psoriasin in BC cells and further 
utilized for in vitro BC cellular function assays. Association 
between Psoriasin expression and survival of patients with BC 
was evaluated using Kaplan‑Meier survival analysis. Psoriasin 
was revealed to be expressed by both bladder epithelia and cancer 
cells as determined by IHC. Increased expression of Psoriasin 
was significantly correlated with a poor overall BC patient 
survival. Overexpression of Psoriasin in the EJ138 cell line 
increased cellular proliferation, adhesion and invasion, whereas 
knockdown exhibited the opposite effect on cellular functions in 
RT112 cells. Matrix metalloprotease (MMP)9 appeared to be the 
most affected of the three MMPs examined in these two BC cell 
lines. The analysis revealed a positive correlation in BC tumours 
between Psoriasin and MMP9. Overall, high Psoriasin expres‑
sion was correlated with poor overall survival in BC patients and 
promoted invasiveness of BC cells via upregulation of MMPs. 
Psoriasin possesses certain prognostic and therapeutic potential 
in BC which requires further exploration.
Introduction
Worldwide, bladder cancer (BC) is the seventh commonest 
malignant tumour in men and the eleventh most common 
tumour for both sexes. The age‑standardised incidence rate 
(per 100,000 person/years) is 9.0 for men and 2.2 for women 
worldwide, and 19.1 for men and 4.0 for women in Europe 
specifically (1). The majority of bladder tumours are transitional 
cell carcinomas (TCCs), with approximately 80% being nonin‑
vasive papillary transitional‑cell carcinomas that are frequently 
amenable to surgical resection. Unfortunately, 50‑70% of 
patients develop tumour recurrence and of those that do, 15% 
have more advanced disease. These patients with advanced 
disease invading the muscle of the bladder, have a significantly 
reduced 5‑year survival rate, due to the increased incidence of 
metastases and failure of available treatments (2,3). Of those 
patients that present at diagnosis with locally advanced, bladder 
muscle invasive TCC, 50% relapse with metastatic diseases (4). 
These poor outcomes, particularly in those with metastatic BC, 
require a better understanding of BC disease progression, such 
that improvements can be made for BC patients.
Psoriasin (otherwise known as S100A7) is an 11.4‑kDa 
secreted protein located on chromosome 1q21 and belongs to 
the S100 protein family (5). In normal human tissues, expres‑
sion of Psoriasin is commonly confined to the epithelia, having 
been initially identified as highly expressed in the epidermis of 
psoriatic skin (6). In terms of cellular functions it is known to 
influence calcium binding and signalling, thus affecting cellular 
proliferation, differentiation, migration and apoptosis (7).
It is of no surprise therefore that aberrant Psoriasin is 
associated to numerous human diseases including cancer. 
Psoriasin overexpression is observed in breast (8), skin (9), 
head and neck (10), prostate (11) and lung cancers (12). In 
breast cancer, upregulated Psoriasin expression is observed 
particularly in ductal carcinoma in situ and invasive tumours 
that are oestrogen and progesterone receptor negative (13). 
Higher Psoriasin expression was associated with poor prog‑
nosis and survival. In addition to the apparent effect on the 
proliferation, adhesion and invasion of cancer cells, Psoriasin 
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can also actively engage in tumour microenvironment and 
signal transduction. For example, Psoriasin is able to promote 
neoangiogenesis by interacting with the receptor for advanced 
glycation end products (RAGE), which results in vascular 
endothelial growth factor (VEGF) upregulation (14). Psoriasin 
can also promote EGF‑induced activation of EGFR with a 
consequent impact on migration and invasion of a ER‑negative 
breast cancer cell line, i.e. MDA‑MB‑231 (15). Psoriasin 
was revealed to be highly expressed and secreted by bladder 
squamous cancer cells (16,17). Determining the protein level 
of Psoriasin in urine has been proposed for early detection and 
monitoring the disease progression (18,19).
To date, the expression of Psoriasin in bladder transitional 
cell carcinoma and its influence on BC cellular function 
remain unknown. The present study aimed to investigate the 
role played by Psoriasin in BC, particularly the most common 
type of BC, i.e. transitional cell carcinoma.
Materials and methods
Materials and cell lines. The human BC cell lines EJ138 (ECACC 
85061108) and RT112 (ECACC cat. no. 85061106; European 
Collection of Animal Cell Culture) were routinely cultured in 
DMEM‑F12 medium, with 10% fetal bovine serum supplemen‑
tation and antibiotics. The EJ138 cell line (ECACC 85061108) 
is the same cell line as T24 shown by both isoenzyme analysis 
and human leukocyte antigen (HLA) profiles. Monoclonal 
mouse anti‑Psoriasin and monoclonal mouse anti‑glyceralde‑
hyde‑3‑phosphate dehydrogenase (GAPDH) antibodies were 
obtained from Novus Biologicals (Novus Biologicals LLC) and 
Santa Cruz Biotechnology, Inc., respectively. All other reagents 
were obtained from Sigma‑Aldrich; Merk KGaA. A bladder 
disease spectrum (urocystic cancer progression) tissue array 
(BL804) was purchased from US Biomax, Inc.
Online data for gene expression profile in BC. Three different 
online datasets were included in the present study. GSE3167 
includes normal urothelium (n=9), superficial transitional cell 
carcinoma (STCC) without carcinoma in situ (CIS) (n=15), 
STCC with CIS (n=13), invasive carcinoma (n=13), CIS (n=5) 
and normal mucosa (n=5) (20). Another cohort of BC was 
GSE32549 which is comprised of BCs of different T stages: Ta 
T1 and T2 (21). A BC cohort from The Cancer Genome Atlas 
(TCGA) was included for a survival analysis using an online 
tool (http://ualcan.path.uab.edu) (22).
Vector construction for Psoriasin overexpression and knock‑
down. Anti‑human Psoriasin hammerhead ribozymes and 
Psoriasin overexpression plasmid vectors were developed and 
used in our previous study (11). The Psoriasin overexpres‑
sion and control plasmids were transfected into EJ138 cells, 
while ribozyme transgene Psoriasin knockdown and control 
were employed in the RT112 cell line. Stable transfectants 
were obtained and verified after 3 weeks of selection using 
blasticidin (5 µg/ml). The selected cells were subsequently 
maintained in the medium containing 0.5 µg/ml blasticidin 
and used for the following experiments.
RNA isolation, reverse transcription‑PCR (RT‑PCR) and 
quantitative PCR (qPCR). TRIzol Reagent (Sigma‑Aldrich; 
Merck KGaA) was used for total RNA extraction and cDNA 
was synthesised using iScript cDNA Synthesis kit (Bio‑Rad 
Laboratories, Inc.). REDTaq ReadyMix PCR reaction mix 
(primer sequences presented in Table I) was utilised for 
PCR under the following cycling conditions: 95̊C for 5 min, 
followed by 36 cycles at 95̊C for 30 sec, 55̊C for 30 sec, 72̊C 
for 40 sec and a final extension at 72̊C for 10 min.
qPCR of BC cell cDNA samples was performed using the 
Icycler IQ5 system (Bio‑Rad Laboratories, Inc.), the Amplifluor 
system (Intergen, Inc.) and qPCR Mastermix (Bio‑Rad 
Laboratories, Inc.) to identify Psoriasin transcript expression, 
along with standards and negative controls. Psoriasin primers 
were designed using Beacon design software (Premier Biosoft 
International), with additional Z sequence (5'‑ACT GAA CCT 
GAC CGT ACA) on the reverse primer complementary to the 
universal Z probe (Intergen, Inc.). Reaction conditions were 
as follows: 95˚C for 12 min, followed by 90 cycles at 95˚C for 
15 sec, 55˚C for 40 sec and 72˚C for 20 sec.
Immunohistochemical (IHC) staining for Psoriasin. A 
bladder disease spectrum tissue array (TMA) (BL804) 
was purchased from US Biomax, Inc. The TMA was 
de‑paraffinised followed by a 20‑min incubation with TBS 
for rehydration. A further 20‑min incubation in 0.6% BSA 
blocking solution was followed by the primary antibody 
(anti‑Psoriasin; dilution 1:100; cat. no. 47C1068; Novus 
Biologicals, Ltd.) for 1 h at room temperature. After 
washing, the sections were incubated in the secondary 
biotinylated antibody (dilution 1:25; biotinylated universal 
pan‑specific antibody, horse anti‑mouse/rabbit/goat IgG, cat. 
no. BA‑1300; Vector Laboratories, Inc.) at room temperature 
for 30 min. An avidin‑biotin complex (Vector Laboratories, 
Inc.) was applied to the TMA and diaminobenzidine chro‑
mogen (Vector laboratories, Inc.) was added in the dark for 
5 min. Counterstaining of the nuclei was performed using 
Gill's hematoxylin (H‑3401; Vector Laboratories, Inc.). The 
TMA was dehydrated with increasing grades of methanol, 
then cleared in xylene and mounted.
Cell proliferation assay. Cells were plated into a 96‑well 
plate (2,000 cells/well for EJ138 and 4,000 cells/well for 
RT112) and proliferation was determined over a period of 
up to 5 days. Cells were stained with 0.5% crystal violet at 
room temperature for 10 min and the absorbance was read at 
a wavelength of 540 nm using a spectrophotometer (Elx800; 
Bio‑Tek Instruments, Inc.).
In vitro invasion assay. Matrigel (50 µg) (BD Matrigel 
Basement Membrane Matrix, cat. no. 354234; BD BioSciences) 
was used to coat Transwell inserts and air‑dried. The coating 
layer was rehydrated before use. Cells (20,000) were added 
to each insert and after 48 h of incubation at 37̊C, any cells 
remaining in the insert were removed with a cotton tip swab 
and the cells that had invaded through the Matrigel were 
fixed in 4% formalin at room temperature for 30 min, stained 
with 0.5% crystal violet for 10 min at room temperature, and 
counted under microscope with a magnification of x200.
Cell‑matrix adhesion assay. Cells (40,000) were placed 
in each well of previously prepared 96‑well plates coated 
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with Matrigel (5 µg/well). Plates were incubated at 37̊C for 
45 min. Media was then discarded and nonadherent cells were 
removed by BSS buffer wash. The remaining adherent cells 
were fixed for 10 min in 4% formaldehyde, followed by a BSS 
wash and 0.5% crystal violet staining at room temperature for 
10 min. The number of adherent cells was then counted under 
a microscope with a magnification of x200.
Wound/scratch assay. Cells were seeded at a density of 
20,000 cells/well for EJ138 and 40,000 cells/well for RT112 
into a 24‑well plate and cultured until confluency. After creation 
of a scratch/wound, the movement of cells to close the wound 
was recorded using an inverted microscope equipped with an 
incubation chamber with a magnification of x100 (EVOS FL 
Auto2; Life Technologies; Thermo Fisher Scientific, Inc.). The 
movement of the cells was quantified using ImageJ (Version 
1.48; https://imagej.nih.gov/ij/).
Western blotting. Cells were lysed using a buffer comprising 
150 mM NaCl, 50 mM Tris, 0.02% sodium azide, 0.5% sodium 
deoxycholate, 1.5% Triton X‑100 (v/v), 1 µg/ml aprotinin, 
5 mM Na3VO4, 1 µg/ml leupeptin, 100 µg/ml phenylmeth‑
ylsulphonylf luoride, 0.1% sodium dodecyl sulfate and 
100 µM dithiothreitol. Protein concentration was determined 
using the Bio‑Rad DC Protein Assay (500‑0116; Bio‑Rad 
Laboratories, Ltd). Protein (20 µg per lane) was loaded and 
separated in 12% sodium dodecyl sulfate‑polyacrylamide 
gel (SDS‑PAGE) followed by tra‑nsfer on to polyvinylidene 
difluoride membranes. Initial 1‑h membrane blocking used 5% 
fat‑free milk in tris (hydroxymethyl) aminomethane‑buffered 
saline (TBS) (pH 7.5) at room temperature, followed by incu‑
bation with mouse anti‑Psoriasin (1:1,000; cat. no. 47C1068; 
Novus Biologicals, Ltd.), mouse anti‑MMP2 (1:1,000; cat. 
no. sc‑13595), mouse anti‑MMP7 (1:1,000; cat. no. sc‑58388), 
rabbit anti‑MMP9 (1:1,000; cat. no. sc‑10737) or mouse 
anti‑GAPDH (1:1,000; cat. no. sc‑47724; all from Santa 
Cruz Biotechnology, Inc.) antibodies overnight at 4̊C. The 
appropriate  horseradish peroxidase‑conjugated  secondary 
antibodies (A5278 anti‑mouse IgG, A6154 anti‑rabbit IgG; 
Sigma‑Aldrich; Merck KGaA) were applied at room tempera‑
ture for 1 h. Visualisation of the membranes after incubation 
with a chemiluminescence reagent used the Syngene gel 
documentation system (G:BOX Chemi XRQ; GeneSys version 
1.5.6.0; Syngene UK).
Statistical analysis. Analysis was performed using SPSS 17.0 
software (SPSS Inc.). The Mann‑Whitney U test was employed 
to analyse non‑normally distributed data, while the two‑sample 
t‑test was utilised for normally distributed data. Pearson correla‑
tion test was used for the correlation analysis. A P‑value at <0.05 
was considered to indicate a statistically significant difference.
Results
Expression of Psoriasin in BC tissues, and correlation with 
clinicopathological features of BC. The expression of Psoriasin 
in BC was first evaluated using two gene array datasets. In the 
cohort (GSE3167) comprised of normal urothelium, superficial 
transitional cell carcinoma (STCC) without/with carcinoma 
in situ (CIS), invasive carcinoma, CIS and normal mucosa, the 
expression of Psoriasin was increased in the invasive carcinomas 
(Fig. 1A). This was further supported by analyses of Psoriasin in 
the other cohort of BC (GSE32549), which revealed an increased 
expression of Psoriasin in invasive BCs including both T1 and 
T2 tumours compared with Ta tumours which were confined 
within the innermost layer of the bladder lining (Fig. 1B). To 
investigate how Psoriasin expression may relate to clinical 
prognosis, Kaplan‑Meier survival analysis was performed for 
Psoriasin expression in the TGGA BC cohort using an online 
tool (http://ualcan.path.uab.edu/cgi‑bin/). It was revealed that a 
high level of Psoriasin expression was significantly correlated 
with poor overall survival in BC patients (P=0.015, Fig. 1C). 
With regard to Psoriasin protein expression levels, IHC analysis 
of Psoriasin in a human bladder disease spectrum tissue array 
demonstrated weak to moderate staining in normal urocystic 
tissues, hyperplasia and chronic inflammation of mucosa 
(Fig. 1D and Table II). Psoriasin was weakly expressed or absent 
from T1 TCC tumours. Strong staining was observed in 2 of 
the 19 T2 TCC tumours. Strong and extensive staining was 
observed in 3 out of 5 squamous cell carcinomas.
Knockdown and overexpression of Psoriasin in BC cell lines. 
Two BC cell lines were examined for mRNA expression of 
Psoriasin using RT‑PCR (Fig. 2A). The expression of Psoriasin 
was relatively higher in RT112 cells in comparison with EJ138 
cells. This allowed us to examine the function of Psoriasin in 
BC cells using these two cell lines to create a pair of opposite 
models, i.e. knockdown of Psoriasin in the RT112 cell line and 
overexpression of Psoriasin in the EJ138 cell line. Psoriasin 
Table I. Primer sequences for PCR and qPCR.
Primer Forward Reverse
Psoriasin 5'‑GAGGTCCATAATAGGCATGA‑3' 5'‑AGCAAGGACAGAAACTCAGA‑3'
Psoriasin (qPCR) 5'‑TGTGACAAAAAGGGCACAAA‑3' 5'‑ACTGAACCTGACCGTACACCCA
  GCAAGGACAGAAACTC‑3'
GAPDH 5'‑GGCTGCTTTTAACTCTGGTA‑3' 5'‑GACTGTGGTCATGAGTCCTT‑3'
GAPDH (qPCR) 5'‑CTGAGTACGTCGTGGAGTC‑3' 5'‑ACTGAACCTGACCGTACAGAGA
  TGATGACCCTTTTG‑3'
Psoriasin ribozyme 5'‑CTGCAGTCACAGGCACTAAGGAAG 5'‑ACTAGTGGCTGGTGTTTGACATT
 TTGGGCTGATGAGTCCGTGAGGA‑3' TCGTCCTCACGGACT‑3'
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knockdown in RT112 and overexpression in EJ138 cell lines 
was achieved using anti‑Psoriasin ribozyme and Psoriasin 
expressing plasmid vectors, respectively. Psoriasin expression 
was confirmed in the transfected cells using RT‑PCR (Fig. 2A) 
and qPCR (Fig. 2B). Overexpression of Psoriasin was estab‑
lished in EJ138 (EJ138PsoExp) compared with EJ138 plasmid 
Table II. IHC staining of Psoriasin in bladder tissues.
 N Negative Weak Moderate Strong
Transitional cell carcinoma 
T1 10 5 4 1 0
T2 19 8 7 2 2
T3 1 0 1 0 0
Tx 1 0 0 1 0
Transitional cell carcinoma 30 13 12 3  2
Squamous cell carcinoma 5 0 1 1 3
Adenocarcinoma 2 2 0 0 0
Undifferentiated carcinoma 1 1 0 0 0
Sarcomatoid carcinoma 3 2 1 0 0
Metastasis 3 0 2 0 1
Normal 6 0 6 0 0
Adjacent normal  5  1  4  0  0
Inflammation  8  1  3  3  1
Hyperplasia 12 0 6 5 1
Benign 5 2 2 1 0
Figure 1. Expression of Psoriasin in BC. (A) Psoriasin expression in a cohort of BC (GSE3167) comprised of normal urothelium (n=9), STCC without CIS 
(n=15), STCC with CIS (n=13), invasive carcinoma (n=13), CIS (n=5) and normal mucosa (n=5) (20). (B) Psoriasin expression was also analysed in another gene 
expression array dataset (GSE32549) which was comprised of non‑invasive papillary carcinoma (Ta, n=40), T1 (n=52) and T2 (n=38) (21). (C) Kaplan‑Meier 
survival analysis indicated the expression of Psoriasin was associated with a poor overall survival (TCGA BC). The cutoff value is the 25th percentile. 
(D) Differential expression of Psoriasin was detected in normal urocystic tissues, adjacent normal urocystic tissue, transitional cell carcinomas and squamous 
cell carcinoma (BL804, US Biomax) using IHC. BC, bladder cancer; STCC, superficial transitional cell carcinoma; CIS, carcinoma in situ; TCGA, The Cancer 
Genome Atlas; IHC, immunohistochemical.
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vector control (EJ138pEF), while decreased expression of 
Psoriasin was revealed in the RT112 Psoriasin knockdown 
cells (RT112PsoKd) in comparison with and RT112 plasmid 
vector control (RT112pEF).
Influence of Psoriasin overexpression and knockdown on BC 
cellular proliferation in vitro. Increased proliferation was 
observed in EJ138 cells which had Psoriasin overexpressed. 
EJ138PsoExp cells had a significantly  increased proliferation 
rate, compared to the control (P<0.001; Fig. 3A). Conversely 
in RT112 cells in which Psoriasin had been knocked down 
(RT112PsoKd) there was decreased proliferation, compared to 
the control (P<0.001; Fig. 3B).
Influence of Psoriasin overexpression and knockdown on BC 
cellular adhesion in vitro. The influence of Psoriasin on the 
adhesive nature of BC cells was examined, with EJ138PsoExp 
cells significantly increased in their adhesive capacity 
compared to the EJ138pEF control cells, (P<0.001; Fig. 3C). 
Whereas knockdown of Psoriasin resulted in a significant 
decrease in adhesiveness of RT112PsoKd cells, compared with 
the corresponding control (P<0.001; Fig. 3D).
Effects of Psoriasin on in vitro migration of BC cells. A wound, 
or scratch assay was utilised to determine the migratory 
capacity of BC cells with either Psoriasin overexpression or 
knockdown. Notably, the EJ138PsoExp Psoriasin overexpressing 
cells did not exhibit any significant alteration in migration 
compared to the control (Fig. 4A). A similar result was also 
observed in RT112Psokd cells, in which the motility was similar 
to that of the RT112pEF cells (Fig. 4B).
Effects of Psoriasin on invasion of BC cells. The EJ138PsoExp 
Psoriasin over‑expressing cells demonstrated a significant 
increase of invasion, compared to the control (P<0.001; 
Fig. 5A). Conversely, this was also confirmed with RT112Psokd 
Psoriasin‑knockdown cells that appeared to be significantly 
less invasive compared with the RT112pEF cells (Fig. 5B).
Psoriasin regulates the function of BC cells via MMPs. In our 
previous study of Psoriasin in prostate cancer, MMPs were 
revealed to be involved in Psoriasin‑promoted invasiveness of 
prostate cancer cells (11). Therefore, the MMP protein present 
in EJ138 and RT112 cells was analysed. Increased expression 
of MMP9 was observed in EJ138PsoExp cells, and reduced 
expression of MMP9 was present in RT112Psokd cells. There 
was no evident alterations observed in the expression of MMP2 
and MMP7 (Fig. 6A). To further investigate the relationship 
between MMP9 and Psoriasin, TCGA online data was used 
again (http://www.linkedomics.org/admin.php) and a positive 
correlation between the mRNA expression of Psoriasin and 
MMP9 was revealed (P<0.05; Fig. 6B).
Discussion
TCC has a five‑year survival rate of >95% for patients with 
small single foci, well‑differentiated papillary tumours 
compared to near 0% survival in those patients with locally 
Figure 2. Expression of Psoriasin in BC cell lines. (A) Expression of Psoriasin in EJ138 and RT112 cell lines (left panel) was examined using PCR. EJ138 
(middle panel) and RT112 (right panel) were transfected with Psoriasin overexpression vectors (EJ138PsoExp) and Psoriasin ribozyme vectors (RT112PsoKd), 
respectively. The empty plasmid vector (pEF) was used as control for the transfection and selection. (B) Psoriasin expression was further verified using real 
time PCR. ***P<0.001. BC, bladder cancer.
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advanced disease and gross nodal metastases (23). Despite 
efforts towards early detection and treatment, there is still 
a significant clinical impact on patients with invasive BC, 
including the morbidity of disease recurrence and progression, 
to the mortality inevitably associated with metastases.
Psoriasin was first discovered as being highly expressed in 
the overproliferative epidermis of psoriatic skin lesions (24). 
Subsequent studies of Psoriasin have implied a role in 
promoting tumour progression, particularly in breast cancer 
and pancreatic cancer, where tumours with high Psoriasin 
expression had greater metastasis and poor prognosis (8,25). 
Increased Psoriasin protein has also been detected in the sera 
of patients with squamous cell carcinomas of the lung (26). 
In the present study, Psoriasin expression was examined in a 
human bladder disease spectrum tissue array. Psoriasin was 
weakly expressed or absent from the normal bladder tissues, 
while increased expression was observed in invasive BCs and 
squamous cell BCs. Highly expressed Psoriasin evident in the 
squamous cell BCs was in line with our previous observation 
of Psoriasin in lung cancers (12) and also findings in bladder 
squamous cell carcinomas (17). The present analyses also 
revealed that Psoriasin expression was upregulated in invasive 
BCs. These results indicated that Psoriasin plays an important 
role during the progression of BC, particularly with local inva‑
sion. Kaplan‑Meier survival analysis revealed that the elevated 
expression levels of Psoriasin were associated with the overall 
survival of patients with BC.
The present study demonstrated that in vitro, overexpres‑
sion of Psoriasin resulted in an increase of proliferation, 
invasion and motility of BC cells. Conversely Psoriasin 
knockdown exhibited the opposite impact on these cellular 
functions. The regulatory role of Psoriasin on the cellular 
functions in BC cells is in keeping with findings from studies 
of Psoriasin in other malignancies (11,25,27). It suggests 
that Psoriasin plays a positive role during the invasive 
growth/expansion of BC.
Figure 3. Influence of Psoriasin on in vitro growth and adhesion of BC cells. (A) Growth of EJ138PsoExp cells was examined in comparison with EJ138pEF control 
at day 3 and day 5. (B) RT112PsoKd cells exhibited reduced growth over a period of up to 5 days compared to the RT112pEF control. (C and D) Impact on adhesion 
to Matrigel was determined in (C) EJ138 and (D) RT112 cells. Three independent experiments were performed. ***P<0.001. BC, bladder cancer.
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In contrast to the inverse correlation between Psoriasin 
expression and adhesion observed in previous studies of other 
cancers (11,12,25), Psoriasin overexpression in EJ138 cells 
enhanced their adhesion while an opposite effect on adhesion 
was evident in the RT112 Psoriasin‑knockdown cells. This 
phenomenon is consistent with some observations in clinical 
Figure 4. Effect of altered Psoriasin expression on the migration of BC cells. Migration of (A) EJ138PsoExp cells and (B) RT112PsoKd cells was determined using 
a wound healing assay in comparison with the corresponding controls. BC, bladder cancer.
Figure 5. Psoriasin overexpression and knockdown alters the invasiveness of BC cells. Transwell invasion assay was employed to determine the influence of 
Psoriasin overexpression and knockdown on the invasion of (A) EJ138 and (B) RT112 cell lines, respectively. Three independent experiments were carried out. 
**P<0.01 and ***P<0.001. BC, bladder cancer.
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practice. For example, non‑muscle invading BC cells often 
exhibit continued growth when they are suspended without 
anchorage within the bladder, forming a ‘pedicle’ which often 
appears similar to water grasses floating in the bladder. In 
contrast, muscle invasive BC often presents with an infiltrating 
growth with a ‘moss like’ appearance within the bladder. This 
implies the more invasive BCs, with poor prognosis may have 
a higher Psoriasin expression, promoting growth and invasion, 
but also a more adherent ‘anchored’ appearing moss‑like 
tumour. The other possibility for the difference in findings 
regarding cellular adhesion compared to other studies, is 
that the present study examined TCC, whereas other studies 
focused on adenocarcinomas of the bladder, within which 
Psoriasin may have a slightly different effect. The regulation 
of Psorisasin on the cellular functions of BC cells is yet to be 
fully examined although two BC cell lines were employed in 
the present study. In order to understand the specific adhesion 
mechanism occurring in these malignant lesions, further study 
is yet to be carried out.
It has been well established that MMPs are important 
within the tumour microenvironment for promoting cancer 
cell invasion and metastatic potential (28). In our previous 
study of Psoriasin in prostate cancer and pancreatic cancer, it 
was revealed that Psoriasin influenced cancer cell invasion via 
regulation of certain MMPs (11,25). Similarly, upregulation of 
MMPs has been observed in breast cancer cells overexpressing 
Psoriasin (29). In the present study, BC cells with overexpres‑
sion of Psoriasin were more invasive and had increased MMP9 
expression, indicating the invasive effects of Psoriasin in BC 
could be brought about by MMPs. In the study on Psoriasin 
in breast cancer cells, interaction of Psoriasin with the cyto‑
plasmic domain of the integrin β6 subunit was implicated in 
the promotion of cellular invasion, however, is remains to be 
confirmed whether this may also be the case for BC cells, and 
the interaction of Psoriasin with partner proteins is worthy of 
further study. Future investigation using a BC patient‑derived 
xenograft (PDX) model and organoid model will help to further 
validate and shed light on the therapeutic potential. Moreover, 
better understanding of the relevant machinery employed by 
Psoriasin in BC cells will help to identify the specificity, i.e. 
in which BC tumours Psoriasin promotes disease progression. 
More specific cell line‑ derived models, along with PDX and 
organoid models can then be employed.
In conclusion, increased expression of Psoriasin in BC was 
associated with cellular invasion, and poor survival of patients 
with BC. Psoriasin promoted in vitro cell growth, adhesion, 
and invasion of BC cell lines. MMP9 may be a key player in 
the Psoriasin‑promoted invasiveness of BC cells. The prog‑
nostic and therapeutic potential of Psoriasin demonstrated in 
BC warrants further investigation.
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